Methods for the treatment of insulin-like growth factor 1 deficiency (IGF-1)

摘要

Insulin-like growth factor 1 (IGF-1) for use in a method to treat a human subject who has a primary deficiency of insulin-like growth factor 1 (IGFD), in which the subject is characterized by the following: at the time of treatment or before initial treatment with IGF-1, it has or had a height of at least 2 standard deviations (SD) below the normal average height for a subject of the same age and sex, and at the time of treatment or before initial treatment with IGF-1, you have or had a blood level of IGF-1 at least 1 SD lower than normal mean levels for a subject of the same age and sex, in which the subject is further characterized by having a blood level of growth hormone (GH), said blood level of GH being at least normal for a subject of the same age and sex, in which the subject does not have a blood level of high affinity GH binding protein that is at least 2 SD lower at normal mean levels, in which the subject does not have Laron syndrome or partial growth hormone insensitivity syndrome, and in which Laron syndrome refers to a patient who has a complete lack of receptor function. growth hormone or complete insensitivity syndrome to growth hormone.